vs
Arcutis Biotherapeutics, Inc.（ARQT）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Arcutis Biotherapeutics, Inc.的季度营收约是RE/MAX Holdings, Inc.的1.8倍（$129.5M vs $71.1M），Arcutis Biotherapeutics, Inc.净利率更高（13.4% vs 2.0%，领先11.4%），Arcutis Biotherapeutics, Inc.同比增速更快（81.5% vs -1.8%），过去两年Arcutis Biotherapeutics, Inc.的营收复合增速更高（61.6% vs -4.7%）
Arcutis Biotherapeutics是一家临床阶段生物制药企业，专注于开发和商业化免疫介导皮肤病领域的创新处方疗法，产品管线覆盖银屑病、特应性皮炎、斑秃等适应症，主要服务美国市场的患者及医疗服务提供者，填补皮肤科诊疗领域的未满足需求。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
ARQT vs RMAX — 直观对比
营收规模更大
ARQT
是对方的1.8倍
$71.1M
营收增速更快
ARQT
高出83.3%
-1.8%
净利率更高
ARQT
高出11.4%
2.0%
两年增速更快
ARQT
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $129.5M | $71.1M |
| 净利润 | $17.4M | $1.4M |
| 毛利率 | 91.0% | — |
| 营业利润率 | 14.2% | 13.1% |
| 净利率 | 13.4% | 2.0% |
| 营收同比 | 81.5% | -1.8% |
| 净利润同比 | 261.2% | -75.2% |
| 每股收益（稀释后） | $0.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARQTRMAX
| Q4 25 | $129.5M | $71.1M | ||
| Q3 25 | $99.2M | $73.2M | ||
| Q2 25 | $81.5M | $72.8M | ||
| Q1 25 | $65.8M | $74.5M | ||
| Q4 24 | $71.4M | $72.5M | ||
| Q3 24 | $44.8M | $78.5M | ||
| Q2 24 | $30.9M | $78.5M | ||
| Q1 24 | $49.6M | $78.3M |
净利润ARQTRMAX
| Q4 25 | $17.4M | $1.4M | ||
| Q3 25 | $7.4M | $4.0M | ||
| Q2 25 | $-15.9M | $4.7M | ||
| Q1 25 | $-25.1M | $-2.0M | ||
| Q4 24 | $-10.8M | $5.8M | ||
| Q3 24 | $-41.5M | $966.0K | ||
| Q2 24 | $-52.3M | $3.7M | ||
| Q1 24 | $-35.4M | $-3.4M |
毛利率ARQTRMAX
| Q4 25 | 91.0% | — | ||
| Q3 25 | 91.2% | — | ||
| Q2 25 | 90.8% | — | ||
| Q1 25 | 86.6% | — | ||
| Q4 24 | 90.3% | — | ||
| Q3 24 | 87.7% | — | ||
| Q2 24 | 88.8% | — | ||
| Q1 24 | 93.4% | — |
营业利润率ARQTRMAX
| Q4 25 | 14.2% | 13.1% | ||
| Q3 25 | 8.6% | 25.0% | ||
| Q2 25 | -17.9% | 19.3% | ||
| Q1 25 | -37.3% | 7.2% | ||
| Q4 24 | -10.7% | 5.9% | ||
| Q3 24 | -87.3% | 19.4% | ||
| Q2 24 | -162.3% | 20.6% | ||
| Q1 24 | -63.8% | 5.8% |
净利率ARQTRMAX
| Q4 25 | 13.4% | 2.0% | ||
| Q3 25 | 7.5% | 5.4% | ||
| Q2 25 | -19.5% | 6.4% | ||
| Q1 25 | -38.1% | -2.6% | ||
| Q4 24 | -15.1% | 8.0% | ||
| Q3 24 | -92.8% | 1.2% | ||
| Q2 24 | -169.6% | 4.7% | ||
| Q1 24 | -71.4% | -4.3% |
每股收益（稀释后）ARQTRMAX
| Q4 25 | $0.14 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.13 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $-0.33 | — | ||
| Q2 24 | $-0.42 | — | ||
| Q1 24 | $-0.32 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $42.9M | $118.7M |
| 总债务越低越好 | $109.0M | $432.2M |
| 股东权益账面价值 | $189.5M | $452.4M |
| 总资产 | $433.0M | $582.5M |
| 负债/权益比越低杠杆越低 | 0.58× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ARQTRMAX
| Q4 25 | $42.9M | $118.7M | ||
| Q3 25 | $47.1M | $107.5M | ||
| Q2 25 | $72.7M | $94.3M | ||
| Q1 25 | $53.1M | $89.1M | ||
| Q4 24 | $71.3M | $96.6M | ||
| Q3 24 | $134.9M | $83.8M | ||
| Q2 24 | $84.3M | $66.1M | ||
| Q1 24 | $190.1M | $82.1M |
总债务ARQTRMAX
| Q4 25 | $109.0M | $432.2M | ||
| Q3 25 | $108.5M | $433.3M | ||
| Q2 25 | $108.0M | $434.4M | ||
| Q1 25 | $107.6M | $435.3M | ||
| Q4 24 | $107.2M | $436.2M | ||
| Q3 24 | $204.6M | $437.2M | ||
| Q2 24 | $203.8M | $438.1M | ||
| Q1 24 | $202.8M | $439.0M |
股东权益ARQTRMAX
| Q4 25 | $189.5M | $452.4M | ||
| Q3 25 | $158.1M | $448.1M | ||
| Q2 25 | $139.0M | $442.4M | ||
| Q1 25 | $142.7M | $433.5M | ||
| Q4 24 | $157.5M | $429.5M | ||
| Q3 24 | $156.6M | $423.1M | ||
| Q2 24 | $186.4M | $418.4M | ||
| Q1 24 | $224.9M | $412.0M |
总资产ARQTRMAX
| Q4 25 | $433.0M | $582.5M | ||
| Q3 25 | $371.0M | $582.2M | ||
| Q2 25 | $352.4M | $574.8M | ||
| Q1 25 | $344.1M | $571.4M | ||
| Q4 24 | $348.9M | $581.6M | ||
| Q3 24 | $437.4M | $578.6M | ||
| Q2 24 | $444.8M | $571.4M | ||
| Q1 24 | $478.5M | $566.7M |
负债/权益比ARQTRMAX
| Q4 25 | 0.58× | 0.96× | ||
| Q3 25 | 0.69× | 0.97× | ||
| Q2 25 | 0.78× | 0.98× | ||
| Q1 25 | 0.75× | 1.00× | ||
| Q4 24 | 0.68× | 1.02× | ||
| Q3 24 | 1.31× | 1.03× | ||
| Q2 24 | 1.09× | 1.05× | ||
| Q1 24 | 0.90× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.2M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | — | $33.5M |
| 自由现金流率自由现金流/营收 | — | 47.1% |
| 资本支出强度资本支出/营收 | 0.0% | 10.4% |
| 现金转化率经营现金流/净利润 | 1.51× | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流ARQTRMAX
| Q4 25 | $26.2M | $40.9M | ||
| Q3 25 | $-1.8M | $17.7M | ||
| Q2 25 | $324.0K | $4.6M | ||
| Q1 25 | $-30.4M | $5.7M | ||
| Q4 24 | $-748.0K | $59.7M | ||
| Q3 24 | $-34.7M | $17.6M | ||
| Q2 24 | $-45.1M | $15.9M | ||
| Q1 24 | $-31.6M | $9.4M |
自由现金流ARQTRMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $246.0K | $2.9M | ||
| Q1 25 | $-31.0M | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | $-34.8M | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率ARQTRMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | 0.3% | 4.0% | ||
| Q1 25 | -47.1% | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | -77.8% | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度ARQTRMAX
| Q4 25 | 0.0% | 10.4% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.1% | 2.2% | ||
| Q1 25 | 0.9% | 2.3% | ||
| Q4 24 | 0.0% | 9.1% | ||
| Q3 24 | 0.3% | 1.7% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.0% | 3.3% |
现金转化率ARQTRMAX
| Q4 25 | 1.51× | 28.39× | ||
| Q3 25 | -0.24× | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARQT
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
